Hyperthermia Cancer Treatment Is Estimated To Witness High Growth Owing To Rising Cancer Incidences

Hyperthermia cancer treatment 

Hyperthermia cancer treatment involves raising the temperature of tumours or the whole body to damage and kill cancer cells or sensitize them to other treatments such as chemotherapy and radiation therapy. The treatment makes use of devices that carefully raise the temperature of tumours and the surrounding tissues at targeted locations in the body. This can be done by using interstitial, intracavitary, or external hyperthermia depending on the location and size of the tumour. The treatment aims to make cancer cells more sensitive to radiation and chemotherapy by damaging their DNA.

The global hyperthermia cancer treatment market is estimated to be valued at US$ 187.05 Bn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The rising incidences of cancer across the globe pose a significant market opportunity for hyperthermia cancer treatment. According to the World Cancer Research Fund International, in 2020, there were an estimated 19.3 million new cancer cases and 10 million cancer deaths worldwide. Hyperthermia cancer treatment offers an effective non-invasive treatment option for various types of cancer including breast cancer, brain tumours, melanoma, lymphoma, and others. Its ability to enhance the effects of chemotherapy and radiation therapy when used in combination makes it an attractive treatment approach. Furthermore, the advantages of hyperthermia such as minimal side effects compared to other therapies and the ability to treat recurrent tumours are expected to drive its adoption in the coming years. With continued technological advancements to improve device efficiency and expand applications in combination with other therapies, the market is expected witness strong growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The hyperthermia cancer treatment market requires significant investment in research and development activities that pose barriers for new entrants.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternatives like chemotherapy and radiotherapy.

Bargaining power of suppliers: Suppliers have low to moderate bargaining power as key components can be procured from different sources.

Threat of new substitutes: Alternatives like immunotherapy and targeted drug therapy pose low threat due to niche application of hyperthermia.

Competitive rivalry: The market is moderately competitive due to presence of established players.

SWOT Analysis

Strength: Hyperthermia provides a non-invasive option with minimal side effects. It can be administered with other therapies to improve clinical outcomes.

Weakness: Safety risks associated with overheating sensitive healthy tissues. Requires skilled personnel for precise application of heat.

Opportunity: Growing application scope in pediatric and geriatric patient groups. Combination with immunotherapy and chemotherapy widens prospects.

Threats: Strong preference for other conventional therapies limits widespread adoption. Lack of clinical evidence deters payer reimbursements.

Key Takeaways

The Global Hyperthermia Cancer Treatment Market Growth is expected to witness high growth due to its effectiveness in combination treatments. The North America region dominates the market currently due to advanced healthcare infrastructure and supportive reimbursement policies for cancer therapies. Europe and Asia Pacific regions also offer lucrative opportunities owing to rising cancer incidences and increasing medical tourism respectively.

Key players operating in the hyperthermia cancer treatment market are MagForce AG, Andromedic, Xianke Medical Equipment, OncoTherm, Celsius42+, Oncotherm, Pyrexar Medical, Yamamoto Vinita, Nanoprobes, Alba Hyperthermia System, Nova Company, Perseon, Omron, Sunny Medical Equipment, OrienTech, BSD Medical, Sensius, Celsius42, Nanjing Greathope, Shanghai Huayuan. The market is fragmented with several emerging players focused on new product innovations and regional expansion strategies.

Regional analysis: The US region dominates due to presence of key market players and supportive cancer control policies. Germany accounts for a major share in Europe owing to government funding for cancer research. The Asia Pacific region is expected to witness highest growth backed by growing awareness, healthcare infrastructure advancement and rising medical tourism.

Explore more information on this topic, Please visit @ https://www.rapidwebwire.com/hyperthermia-cancer-treatment-market-is-expected-to-be-flourished-by-rising-geriatric-population